Biota to acquire the antibacterial assets of MaxThera, Inc.
Biota Holdings Limited (ASX:BTA) today announced the acquisition of the assets and
drug development programs of MaxThera, Inc, an antibacterial drug discovery company
located in Boston, USA. The acquisition is subject to the satisfaction of certain
conditions which Biota anticipates will be met in the near future.
MaxThera has developed a high quality suite of validated novel bacterial targets and
early stage antibacterial programs aimed at developing compounds to treat serious
bacterial infections, including those that are resistant to existing antibiotics. The
lead program targets inhibitors of an essential bacterial enzyme in the Coenzyme-A
biosynthetic pathway. Coenzyme-A is responsible for a large number of metabolic
processes in bacteria.
Biota’s Chief Executive Officer, Peter Cook, commented “This acquisition confirms Biota’s
strategy to increase its portfolio of drugs in development and to expand beyond
antivirals into other anti-infectives. MaxThera’s portfolio of new targets and novel
inhibitor structures are highly complementary to Biota’s own innovative programs and
the two organisations have very similar systems and discovery strategies.�
Under the terms of the Agreement, Biota will acquire the assets of MaxThera for
US$1.2m in cash and US$300,000 in Biota shares. The shares will be issued following
completion and will be released from escrow to MaxThera shareholders in two equal
tranches at six and twelve months. MaxThera shareholders are also entitled to receive
twelve (12) percent of all upfront and milestone payments received by Biota if the two
main programs are licensed.
Biota intends to accelerate the development of the lead program and invest up to
US$15 million, assuming development milestones are achieved. The investment will
be in approximately equal instalments over the next 3 to 5 years.
Dr Ania Knap (President and Chief Scientific Officer) and Dr Roger Frechette (Head
of Medicinal Chemistry), MaxThera’s principal scientists and main shareholders, will
maintain their current program involvement at the company’s facilities in Boston.
Their capabilities and commitment to the program are highly valued by Biota.
In line with accepted accounting practice and Biota’s research and development policy,
the majority of the upfront consideration will be expensed in the F2010 financial
statements.
any comments?
- Forums
- ASX - By Stock
- BTA
- biota goes shopping
biota goes shopping
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)